Down 75%. Is Agenus Stock a Buy on the Dip?
The past nine months have been rough ones to be an (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.
Investment bank analysts on Wall Street who follow the Massachusetts-headquartered cancer drug developer think it's been underappreciated. For example, B. Riley recently reiterated a buy rating for Agenus with a $5 price target.
Agenus shares could deliver an enormous return if they get anywhere near Wall Street estimates. The stock has been trading below $1 per share since the company presented clinical trial results for its lead candidate last October.
Source Fool.com
Agenus Inc. Stock
€0.41
-1.970%
Currently there is a rather positive sentiment for Agenus Inc. with 4 Buy predictions and 2 Sell predictions.
With a target price of 36 € there is potential for a 8599.86% increase which would mean more than doubling the current price of 0.41 € for Agenus Inc..
